Anixa Biosciences, Inc. (Nasdaq: ANIX) has reported positive results from a Phase 1 clinical trial of its breast cancer vaccine for Triple Negative breast cancer…
December 12, 2023
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has announced positive initial topline data from its ongoing Phase 2a clinical trial of its novel and highly…
Vistagen Therapeutics (Nasdaq: VTGN) has announced the pricing of a $100 million underwritten offering of its common stock and warrants. Vistagen intends to use the…
October 02, 2023
Next-Gen Bipolar Disorder Treatment Progressing, Says Alzamend
Clinical stage biopharmaceutical company, Alzamend Neuro (Nasdaq: ALZN), has received a “Study May Proceed” letter from the FDA for a Phase IIA clinical study of…